A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults
Eligible age
18+ yrs
Accepts
All genders
Locations
10 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this phase 3 study is to learn the safety, tolerability and immunogenicity of revaccination with RSVpreF at approximately 1-, 2-, and 3-year intervals to inform the revaccination interval in immunocompromised adults. This study is seeking participants who are 18 years of age and older and will be grouped based on prior RSV vaccination history. Participants are required to be immunocompromised per study protocol. All participants in this study will receive 1 shot to their arm of a RSVPreF vaccine. Participants will take part in this study for about 12 months and will need to visit the clinical study site at least 4 times.
Sponsor: Pfizer
Where it's recruiting
Los Angeles
Washington D.C.
Decatur
Iowa City
Baltimore
St Louis
New York · Rochester
Durham
Duncansville
DeSoto
Source: ClinicalTrials.gov · NCT07768345 · last updated 2026-10-14